[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562370":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":52,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":77,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Equipmed USA LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"A single arm, full face clinical study.","OTHER","Dermapen 4 in conjunction with MG-CLR serum",[13],"Combination Product: Dermapen 4™",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"COMBINATION_PRODUCT","Dermapen 4™","Dermapen 4™ conjunction with MG-CLR",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Stene Marshal","CONTACT","(949) 798 6207","stene@dermapenworld.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Aahan Sachdev","9880755883","aahan.sachdev@msclinical.com",[32],{"facility":33,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Skin Wellness Dermatology","Birmingham","Alabama","35209","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-86.80249,33.52066,{"lat":43,"lon":42},[46,50],{"name":47,"role":24,"phone":48,"phoneExt":20,"email":49},"Jordan Rubin","205.678.7518","jrubin@skinwellness.com",{"name":51,"role":24,"phone":20,"phoneExt":20,"email":20},"COREY LOUIS HARTMAN",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100562370","phase-2-a-full-face-study-to-evaluate-the-efficacy-of-dermapen-4-microneedling-device-in-addition-with-mg-clr-serum-for-acne-treatment-over-12-weeks-100562370",false,"NCT06602284","A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.","A Full Face, Baseline Controlled Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Conjunction with MG-CLR Serum for Acne Treatment Over 12 Weeks.","Inclusion Criteria:\n\n1. Female subjects aged between 18-45 years (both ages inclusive)\n2. Fitzpatrick skin phototype I to VI.\n3. Subjects having IGA score of 2 and 3.\n4. Subjects who have not received any kind of treatment for acne 1 month before the start of the study.\n5. Subject free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other skin conditions on the face.\n6. Subjects who agree not to use any other product\u002Ftreatment\u002Fhome remedy\u002F except the provided products on their face during the study period\n\nExclusion Criteria:\n\n1. Subjects with known skin condition that may impact the assessment.\n2. Subjects with active Herpes labialis infection.\n3. Subjects known to have bleeding and clotting disorders (self-declared).\n4. Subjects known to have connective tissue disorders.\n5. Subjects with any other signs of significant local irritation or skin disease.\n6. Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data.",true,"FEMALE","18 Years","45 Years",{"count":66,"type":67},10,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE2","PHASE3","This study is conducted to check how well the Dermapen 4™ microneedling device works with MG-CLR serum for treating acne over 12 weeks.",[74],"Acne",[76],"dermapen, microneedling, acne","NOT_YET_RECRUITING","2024-09-16",{"date":80,"type":81},"2024-09-19","ACTUAL",{"date":83,"type":67},"2024-10",{"date":85,"type":67},"2025-03",{"name":5,"class":6},1]